Sanofi's first big trial for top cancer drug ends in setback

Amber Tong

One of Sanofi’s top late-stage prospects has failed its first major test in breast cancer, dimming blockbuster hopes even as the French drugmaker doubles down …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Sanofi's first big trial for top cancer drug ends in setback

Amber Tong

Sign up to read this article for free.

Director Oligonucleotide R&D

Bachem

Bubendorf, BL, Switzerland

Where the money is: The top 100 venture investors in biotech

J&J seeks to stop Samsung Bioepis from licensing Stelara biosimilar

Compounders sue FDA over removal of semaglutide from official shortage list

Lilly pays $10M upfront for Organovo’s FXR agonist program

Candel's viral therapy shows promising survival in small pancreatic cancer study

How AI can address ongoing challenges in the life sciences industry

Sanofi's first big tri­al for top can­cer drug ends in set­back

Sign up to read this article for free.

Bachem

Bubendorf, BL, Switzerland

Sanofi's first big trial for top cancer drug ends in setback